Mediating Effect Of The Motivation For Medication Use On Disease Management And Medication Adherence Among Community-Dwelling Patients With Schizophrenia

References

• National Institute of Mental Health. Mental health information. 2018 Available from: https://www.nimh.nih.gov/health/statistics/schizophrenia.shtml Accessed 39, 2019.
   Google Scholar
• Ministry of Health and Welfare. The numbers of individuals with disabilities. 2016 Available from: http://www.mohw.gov.tw/cht/DOS/Statistic.aspx?f_list_no=312&fod_list_no=4198 Accessed 410, 2017.
   Google Scholar
• Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first- generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31–41. doi:10.1016/S0140-6736(08)61764-X19058842
   PubMed Web of Science ®Google Scholar
• Miller BJ, Bodenheimer C, Crittenden K. Second-generation antipsychotic discontinuation in first episode psychosis: an updated review. Clin Psychopharmacol Neurosci. 2011;9(2):45–53. doi:10.9758/cpn.2011.9.2.4523429653
   PubMedGoogle Scholar
• Sendt KV, Tracy DK, Bhattacharyya S. A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Res. 2015;225(1):14–30. doi:10.1016/j.psychres.2014.11.00225466227
   PubMed Web of Science ®Google Scholar
• Rong JR, Yang TY, Laiu WI, Hung TM, Hung FF, Shiau SJ. Exploring essential competences and credentialing model of community psychiatric mental health nursing. J Psychiatr Ment Health Nurs. 2008;3(2):1–9.
   Google Scholar
• Huang JY, Chen HM. Concept analysis of medication adherence in patients with chronic disease. J Nurs. 2014;61(3):112–118. doi:10.6224/JN.61.3.112.
   Google Scholar
• World Health Organization. Adherence to long-term therapies: policy for action. 2001 Available from: http://www.who.int/chp/knowledge/publications/adherencerep.pdf Accessed 410, 2017.
   Google Scholar
• Xiao J, Mi W, Li L, Shi Y, Zhang H. High relapse rate and poor medication adherence in the Chinese population with schizophrenia: results from an observational survey in the people’s republic of China. Neuropsychiatr Dis Treat. 2015;11:1161–1167. doi:10.2147/NDT.S7236726056450
   PubMed Web of Science ®Google Scholar
• Emsley R, Oosthuizen PP, Koen L, Niehaus DJ, Martinez G. Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for two years: a 3-year open-label clinical study. J Clin Psychiatry. 2012;73(4):541–547. doi:10.4088/JCP.11m07138
   Google Scholar
• Zipursky RB, Menezes NM, Streiner DL. Risk of symptom recurrence with medication dis- continuation in first-episode psychosis: a systematic review. Schizophr Res. 2014;152:408–414. doi:10.1016/j.schres.2013.08.00123972821
   PubMed Web of Science ®Google Scholar
• Dilla T, Ciudad A, Alvarez M. Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia. Patient Prefer Adherence. 2013;7:275–284. doi:10.2147/PPA.S4160923589681
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Liu-Seifert H, Kulkarni PM, et al. Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with a suboptimal prior response. J Clin Psychiatry. 2009;70(7):990–996. doi:10.4088/JCP.08m0422119497244
   PubMed Web of Science ®Google Scholar
• Leclerc E, Noto C, Bressan RA, Brietzke E. Determinants of adhe- rence to treatment in first-episode psychosis: a comprehensive review. Rev Bras Psiquiatr. 2015;37(2):168–176. doi:10.1590/1516-4446-2014-153925946398
   PubMed Web of Science ®Google Scholar
• Novick D, Montgomery W, Treuer T, Aguado J, Kraemer S, Haro JM. Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study. BMC Psychiatry. 2015;15(1):1–8. doi:10.1186/s12888-015-0560-425609320
   PubMed Web of Science ®Google Scholar
• Shuler KM. Approaches to improve adherence to pharmacotherapy in patients with schizo phrenia. Patient Prefer Adherence. 2014;8:701–714. doi:10.2147/PPA.S5937124868149
   PubMed Web of Science ®Google Scholar
• Higashi K, Medic G, Littlewood KJ, Diez T, Granstrom O, De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013;3(4):200–218. doi:10.1177/204512531247401924167693
   PubMedGoogle Scholar
• Eticha T, Teklu A, Ali D, Solomon G, Alemayehu A. Factors associated with medication adherence among patients with schizophrenia in Mekelle, Northern Ethiopia. PLoS One. 2015;10(3):1–11. doi:10.1371/journal.pone.0120560
   Web of Science ®Google Scholar
• Velligan DI, Sajatovic M, Hatch A, Kramata P, Docherty JP. Why do psychiatric patients stop antipsychotic medication? a systematic review of reasons for nonadherence to medication in patients with severe mental illness. Patient Prefer Adherence. 2017;11:449–468. doi:10.2147/PPA.S12465828424542
   PubMed Web of Science ®Google Scholar
• Ramachandran AS, Ramanathan R, Praharaj SK, Kanradi H, Sharma PSVN. A cross- sectional, comparative study of insight in schizophrenia and bipolar patients in remission. Indian J Psychol Med. 2016;38(3):207–212. doi:10.4103/0253-717627335515
   PubMedGoogle Scholar
• Mekonnen M, Boru B, Yohannis Z, Abebaw D, Birhanu A. Level of perceived social support and associated factors among people with schizophrenia attending outpatient department at amanuel mental specialized hospital. J Psychopharmacol. 2019;22:1–7. doi:10.4172/2378-5756.1000461
   Google Scholar
• National Academy for Educational Reasearch. Theories of motivation. 2000 Available from: http://terms.naer.edu.tw/detail/1309154/ Accessed 410, 2017.
   Google Scholar
• Ajzen I. The theory of planned behavior. Organ Behav Hum Decis Process. 1991;50:179–211. doi:10.1016/0749-5978(91)90020-T
   Web of Science ®Google Scholar
• Chang YT, Tao SG, Lu CL. Qualitative inquiry into motivators for maintaining medication adherence among Taiwanese with schizophrenia. Int J Ment Health Nurs. 2013;22(3):272–278. doi:10.1111/j.1447-0349.2012.00864.x22882876
   PubMed Web of Science ®Google Scholar
• Rungruangsiripan M, Sitthimongkol Y, Maneesriwongul W, Talley S, Vorapongsathorn T. Mediating role of illness representation among social support, therapeutic alliance, the experience of medication side effects, and medication adherence in persons with schizophrenia. Arch Psychiatr Nurs. 2011;25(4):269–283. doi:10.1016/j.apnu.2010.09.00221784285
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Washington: Am J Psychiatry; 2013.
   Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Washington: Am J Psychiatry; 2000.
   Google Scholar
• Startup M, Jackson MC, Bendix S. The concurrent validity of the Global Assessment of Functioning (GAF). Br J Clin Psychol. 2002;41(4):417–422. doi:10.1348/01446650276038753312437796
   PubMed Web of Science ®Google Scholar
• Chang TJ, Hwu HG, Wei FW. The inter-rater reliability of brief psychiatric rating scale (BPRS). Chin Soc Neurol Psychiatry Bull. 1986;12(1):29–36.
   Google Scholar
• Waddell L, Taylor M. A new self-rating scale for detecting atypical or second-generation antipsychotic side effects. J Psychopharmacol. 2008;22(3):238–243. doi:10.1177/026988110708797618541624
   PubMed Web of Science ®Google Scholar
• Nystazaki M, Tsapakis E, Hadjulis M, Alevizopoulos G. Validation of the Glasgow Antipsychotic Side-Effect Scale (GASS) in Greece. J Child Psychol Psychiatry. 2014;1(4):1–6. doi:10.15406/jpcpy.2014.01.00024
   Google Scholar
• Tracey TJ, Kokotovic AM. Factor structure of the working alliance inventory. J Consult Clin Psychol. 1989;1(3):207–210. doi:10.1037/1040-3590.1.3.207
   Google Scholar
• Munder T, Wilmers F, Leonhart R, Linster HW, Barth J. Working Alliance Inventory-Short Revised (WAI-SR): psychometric properties in outpatients and inpatients. Clin Psychol Psychother. 2010;17(3):231–239. doi:10.1002/cpp.65820013760
   PubMed Web of Science ®Google Scholar
• Andrusyna TP, Tang TZ, DeRubeis RJ, Luborsky L. The factor structure of the Working Alliance Inventory in cognitive-behavioral therapy. J Psychother Pract Res. 2001;10(3):173–178.11402080
   PubMedGoogle Scholar
• Yu DS, Lee DT, Woo J. Psychometric testing of the Chinese version of the Medical Outcomes Study Social Support survey (MOS-SSS-C). Res Nurs Health. 2004;27(2):135–143. doi:10.1002/nur.2000815042639
   PubMed Web of Science ®Google Scholar
• Alonso FA, Montes MA, Menendez VC, Pereira MG. Cultural adaptation and validation of the medical outcomes study social support survey questionnaire (MOS-SSS). Acta Med Port. 2006;20(6):525–534.
   Google Scholar
• Yen CF, Yeh ML, Chong MY, Chung HH, Chen CS. A multidimensional assessment of insights in schizophrenic patients. Kaohsiung J Med Sci. 2001;17(5):253–260.11517864
   PubMedGoogle Scholar
• Chan SC, Chan CC, Siu AM, Poon PK. Stage of change in self- management of chronic diseases: psychometric properties of the Chinese version of the University of Rhode Island Change Assessment (C-URICA) Scale. Rehabil Psychol. 2007;52(1):103–112. doi:10.1037/0090-5550.52.1.103
   Web of Science ®Google Scholar
• Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000;42(3):241–247. doi:10.1016/S0920-9964(99)00130-910785582
   PubMed Web of Science ®Google Scholar
• Kao YC, Liu YP. Compliance and schizophrenia: the predictive potential of insight into illness, symptoms, and side effects. Compr Psychiatry. 2010;51(6):557–565. doi:10.1016/j.comppsych.2010.03.00720965300
   PubMed Web of Science ®Google Scholar
• Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986;51(6):1173–1182. doi:10.1037/0022-3514.51.6.11733806354
   PubMed Web of Science ®Google Scholar
• Hayes AF. Introduction to Mediation, Moderation, and Conditional Process Analysis: A Regression-Based Approach. New York: Guilford Press; 2013.
   Google Scholar
• MacKinnon DP, Lockwood CM, Hoffman JM, West SG, Sheets V. A comparison of methods to test mediation and other intervening variable effects. Psychol Methods. 2002;7(1):83–104. doi:10.1037/1082-989X.7.1.8311928892
   PubMed Web of Science ®Google Scholar
• Preacher KJ, Hayes AF. SPSS and SAS procedures for estimating indirect effects in simple mediation models. Behav Res Methods Instrum Comput. 2004;36(4):717–731. doi:10.3758/BF0320655315641418
   PubMedGoogle Scholar
• Sobel ME. Asymptotic confidence intervals for indirect effects in structural equation models. Sociol Methodol. 1982;13:290–312. doi:10.2307/270723
   Google Scholar
• Abrar S, Shoka A, Arain N, Widuch-Mert C. Landing on the MARS! BJMP. 2012;5(3):9–14.
   Google Scholar
• British Medical Journal. Correlation and regression. 2011 Available from: https://www.bmj.com/about-bmj/resources-readers/publications/statistics-square-one/11-correlation-and-regression Accessed 106, 2018.
   Google Scholar
• Hill M, Crumlish N, Whitty P, et al. Nonadherence to medication four years after the first episode of psychosis and associated risk factors. Psychiatric Serv. 2010;61(2):189–192. doi:10.1176/ps.2010.61.2.189
   Web of Science ®Google Scholar
• Prochaska JO, Redding CA, Evers KE. The transtheoretical model and stages of change In: Glanz K, Barbara KR, Viswanath K, editors. Health Behavior: Theory, Research, and Practice. San Francisco: Jossey-Bass A Wiley Brand; 2015:125–148.
   Google Scholar
• Fai EK, Anderson C, Ferreros V. Role of attitudes and intentions in predicting adherence to oral diabetes medications. Endocr Connect. 2017;6(2):63–70. doi:10.1530/EC-16-009328087609
   PubMed Web of Science ®Google Scholar
• Wu P, Liu N. Association between patients’ beliefs and oral antidiabetic medication adherence in a Chinese type 2 diabetic population. Patient Prefer Adherence. 2016;10:1161–1167. doi:10.2147/PPA.S10560027390519
   PubMed Web of Science ®Google Scholar
• Lin CY, Updegraff JA, Pakpour AH. The relationship between the theory of planned behavior and medication adherence in patients with epilepsy. Epilepsy Behav. 2016;61:231–236. doi:10.1016/j.yebeh.2016.05.03027390026
   PubMed Web of Science ®Google Scholar
• Ho CP, Lee TJF. An evaluation of medication adherence in hypertensive patients using the theory of planned behavior. Value Health. 2014;17(7):763. doi:10.1016/j.jval.2014.08.270
   PubMed Web of Science ®Google Scholar
• Jeng KS, Huang HK, Lee CF, Shao WC, Chang YF. The effect of a project to enhance drug compliance of psychiatric patients who live in remote mountainous areas. J Med Health. 2014;3(1):77–78.
   Google Scholar
• Lin HH, Kuo YP, Lin ECL, Chen PS, Chen KC. A pilot study of the effect of an illness management group on patients with schizophrenia living in the community. J Nurs Healthcare Res. 2014;10(1):15–22.
   Google Scholar
• Chien WT, Mui J, Gray R, Cheung E. Adherence therapy versus routine psychiatric care for people with schizophrenia spectrum disorders: a randomized controlled trial. BMC Psychiatry. 2016;16(1):1–14. doi:10.1186/s12888-016-0744-626739960
   PubMed Web of Science ®Google Scholar
• Cook PF, Emiliozzi S, Waters C, El DH. Effects of telephone counseling on antipsychotic adherence and emergency department utilization. Am J Manag Care. 2008;14(12):841–846.19067501
   PubMed Web of Science ®Google Scholar
• Schulz M, Gray R, Spiekermann A, Abderhalden C, Behrens J, Driessen M. Adherence therapy following an acute episode of schizophrenia: a multi-center randomized controlled trial. Schizophr Res. 2013;146(1):59–63. doi:10.1016/j.schres.2013.01.02823452506
   PubMed Web of Science ®Google Scholar
• Staring A, Van der Gaag M, Koopmans G, et al. Treatment adherence therapy in people with psychotic disorders: randomized controlled trial. Br J Psychiatry. 2010;197(6):448–455. doi:10.1192/bjp.bp.110.07728921119150
   PubMed Web of Science ®Google Scholar
• Chien WT, Mui JH, Cheung EF, Gray R. Effects of motivational interviewing-based adherence therapy for schizophrenia spectrum disorders: a randomized controlled trial. Trials. 2015;16(1):1–14. doi:10.1186/s13063-015-0785-z25971836
   PubMed Web of Science ®Google Scholar
• Stirratt MJ, Dunbar-Jacob J, Crane HM, et al. Self-report measures of medication adherence behavior: recommendations on optimal use. Transl Behav Med. 2015;5(4):470–482. doi:10.1007/s13142-015-0315-226622919
   PubMed Web of Science ®Google Scholar
• Shi L, Liu J, Fonseca V, Walker P, Kalsekar A, Pawaskar M. Correlation between adherence rates measured by MEMS and self-reported questionnaires: a meta-analysis. Health Qual Life Outcomes. 2010;8(1):1–7. doi:10.1186/1477-7525-8-9920053296
   PubMed Web of Science ®Google Scholar